Supernus price target raised to $14 from $12 at Stifel After Supernus stated that it believes it is on track to reach cash flow break-even, Stifel thinks the launches of the company's Oxtellar and Trokendi drugs are going well. Stifel believes that uptake of the company's Trokendi XR drug could improve, and it keeps a Buy rating on the stock.
Court rules in favor of Supernus on two patents in suit with Actavis The U.S. District Court for the District of New Jersey entered judgment against Actavis, now known as Allergan (AGN), and in favor of Supernus (SUPN) as to the '898 and '131 patents disputed in a lawsuit between the two companies. The court found against Supernus and in favor of Actavis as to the '600 patent, according to a court filing. The Patents-in-Suit relate to Supernus' Oxtellar XR drug indicated for the treatment of seizures. Shares of Supernus are up 29% in afternoon trading following the court ruling.